The GLP-1 receptor agonist market is still primarily anchored in type 2 diabetes management, where these drugs improve glycemic control, reduce HbA1c levels, and mitigate cardiovascular risks
There are trials that are not well conducted and are very, very biased, she said
Proposed risk factors include a change in bile acid production and secretion, suppressed cholecystokinin secretion, decreased emptying time, prolonged gallbladder refilling, and weight loss
Between Wegovy and Mounjaro, both are well tolerated, but Mounjaro tends to show lower nausea rates in head-to-head data
The purity of the dialyzed protein was checked with SDS-PAGE
Novo Nordisk achieves 74% growth surge, clinching fastest-growing pharma title